C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Invests $478,000 in Exact Sciences Co. (NASDAQ:EXAS)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS) during the 4th quarter, HoldingsChannel reports. The firm bought 8,508 shares of the medical research company’s stock, valued at approximately $478,000.

A number of other hedge funds also recently made changes to their positions in the company. Chicago Partners Investment Group LLC increased its holdings in Exact Sciences by 1.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock worth $651,000 after purchasing an additional 158 shares during the last quarter. Perigon Wealth Management LLC lifted its stake in Exact Sciences by 3.2% in the fourth quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock valued at $474,000 after buying an additional 264 shares during the last quarter. Sanctuary Advisors LLC boosted its stake in Exact Sciences by 2.0% during the 4th quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company’s stock valued at $763,000 after purchasing an additional 269 shares during the period. Huntington National Bank boosted its position in shares of Exact Sciences by 838.1% during the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after buying an additional 352 shares during the period. Finally, CIBC Asset Management Inc grew its stake in shares of Exact Sciences by 6.1% in the third quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company’s stock worth $442,000 after purchasing an additional 371 shares in the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Price Performance

Shares of NASDAQ:EXAS opened at $50.48 on Thursday. The company has a market cap of $9.34 billion, a price-to-earnings ratio of -43.14 and a beta of 1.24. The business has a 50 day moving average price of $55.41 and a 200 day moving average price of $60.10. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. Research analysts predict that Exact Sciences Co. will post -1.1 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. TD Cowen increased their price objective on shares of Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Bank of America decreased their price target on Exact Sciences from $75.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Stifel Nicolaus lowered their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Piper Sandler dropped their target price on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Finally, Citigroup dropped their price target on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $72.76.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.